ArQule, Inc. Enrolls First Patient in Phase 1 Trial of ARQ 736, Its Pan-RAF Inhibitor

WOBURN, Mass.--(BUSINESS WIRE)--ArQule, Inc. (NASDAQ: ARQL) today announced the commencement of patient dosing in a Phase 1 clinical trial with ARQ 736, a small molecule inhibitor of the RAF kinases.